drugset
drugset / Trial / NCT03728972

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

NCT03728972 ↗

Phase 2 Active not recruiting 19 enrolled Memorial Sloan Kettering Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.

Timeline

Start
2018-11-09
Primary completion
2025-06-15
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

extranodal nasal NK/T cell lymphoma